蠕形螨睑缘炎治疗药物——洛替拉纳  

A novel drug for the treatment of demodex blepharitis:lotilaner

作　　者：杨佳丽[1] 张岩[1] 陈月[1] 封宇飞 张海英[1] YANG Jiali;ZHANG Yan;CHEN Yue;FENG Yufei;ZHANG Haiying(Department of Pharmacy,People's Hospital of Peking University,Beijing 100044,China)

机构地区：[1]北京大学人民医院药学部,北京100044

出　　处：《临床药物治疗杂志》2024年第6期14-17,共4页Clinical Medication Journal

摘　　要：洛替拉纳是一种新型异口恶唑啉类化合物,是γ-氨基丁酸(GABA)受体非竞争性拮抗剂。2023年7月,FDA批准其滴眼液上市,用于治疗成人蠕形螨睑缘炎。本品可通过拮抗GABA受体使眼部寄生虫表现出痉挛性麻痹,导致其饥饿和死亡。本文拟就洛替拉纳滴眼液的药理作用、药动学、临床评价、安全性、用法用量等进行综述。Lotilaner is a novel isoxazoline compound and a non-competitive antagonist of gamma-aminobutyric acid(GABA)receptors.In July 2023,the U.S.FDA approved lotilaner for the treatment of adult Demodex blepharitis.By inhibiting GABA receptors,lotilaner can cause spastic paralysis in Demodex mites,leading to starvation and death.This article aims to review the pharmacology,pharmacokinetics,clinical evaluation,safety,dosage and administration of lotilaner.

关 键 词：洛替拉纳 蠕形螨睑缘炎 Γ-氨基丁酸受体 临床研究 

分 类 号：R979.9[医药卫生—药品]